SBFM
Sunshine Biopharma, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.21
P/S
0.16
EV/EBITDA
0.61
DCF Value
$-483.53
FCF Yield
-93.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
33.8%
Operating Margin
-17.2%
Net Margin
-16.5%
ROE
-25.0%
ROA
-185.2%
ROIC
193.5%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| FY 2025 | $36.3M | $-6.0M | $-1.44 |
| Q3 2025 | $9.4M | $-883.8K | $-0.19 |
| Q2 2025 | $9.4M | $-1.8M | $-7.80 |
| Q1 2025 | $8.9M | $-1.2M | $-0.44 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
CA
Exchange
NASDAQ
Beta
1.60
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.